Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center" colspan="3">Combination index values at</td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center">IC50</td><td class="align_center">IC70</td><td class="align_center">IC75</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">CNE2</td><td class="align_center">0.9</td><td class="align_center">0.8</td><td class="align_center">0.9</td></tr><tr><td class="align_left">HNE1</td><td class="align_center">0.6</td><td class="align_center">0.5</td><td class="align_center">0.5</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>IC50: half maximal inhibitory concentration (IC50) values. IC70: 70% inhibitory concentration values. IC75: 75% inhibitory concentration values. CI: combination index. <br/></td></tr></table>

The combination indexes (CIs) of cetuximab and cisplatin in CNE2 and HNE1 cells.

Biochemistry Research International

tab1

Table 1

Table 1: Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway 

Table 1 | Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway 